Clovis Oncology Inc (CLVS)

54.67
0.31 0.56
NASDAQ : Health Care
Prev Close 54.98
Open 54.97
Day Low/High 54.31 / 55.14
52 Wk Low/High 11.57 / 116.75
Volume 100.65K
Avg Volume 1.79M
Exchange NASDAQ
Shares Outstanding 44.77M
Market Cap 2.44B
EPS -9.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.

Clovis Oncology Announces First Quarter 2017 Operating Results

Clovis Oncology Announces First Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce First Quarter 2017 Financial Results And Host Webcast Conference Call On May 3

Clovis Oncology To Announce First Quarter 2017 Financial Results And Host Webcast Conference Call On May 3

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Clovis Oncology Announces Data Presentations At AACR Annual Meeting 2017

Clovis Oncology Announces Data Presentations At AACR Annual Meeting 2017

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

Look for Clovis Oncology to Resume Its Advance

Look for Clovis Oncology to Resume Its Advance

More gains await patient CLVS holders.

Notable Wednesday Option Activity: CLVS, KMG, NYLD

Notable Wednesday Option Activity: CLVS, KMG, NYLD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc , where a total volume of 7,551 contracts has been traded thus far today, a contract volume which is representative of approximately 755,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.5% of CLVS's average daily trading volume over the past month, of 1.8 million shares.

Goldman Sachs Raises Clovis Oncology Price Target to $75

Goldman Sachs Raises Clovis Oncology Price Target to $75

Clovis Oncology closed trading below $67 on Tuesday.

6 Stocks Trending Up With Major Volume

6 Stocks Trending Up With Major Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer

Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer

Clovis Oncology, Inc. (NASDAQ:CLVS) announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in...

Clovis Oncology Announces 2016 Operating Results

Clovis Oncology Announces 2016 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for 2017.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.

Clovis Oncology Inc Reaches Analyst Target Price

Clovis Oncology Inc Reaches Analyst Target Price

In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $63.71, changing hands for $65.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Clovis Oncology To Announce Fourth Quarter/Year-End 2016 Financial Results And Host Webcast Conference Call On February 22

Clovis Oncology To Announce Fourth Quarter/Year-End 2016 Financial Results And Host Webcast Conference Call On February 22

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017, after the close of the U.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Clovis Oncology To Present At The 35th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 35th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares.

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.